Erythrocytes-based synthetic delivery systems: transition from conventional to novel engineering strategies

Bhateria, Manisha; Ramakrishna, Rachumallu; Singh, Rajbir; Bhatta, Rabi Sankar

doi:10.1517/17425247.2014.927436

Cited by 33 publications

(23 citation statements)

References 138 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The loading of the potential antitumor drug GA bestowed on the nanocarrier new antitumor efficacy. The combination of RBCm and PLGA has been shown to enhance the stability and biocompatibility of a composite carrier compared with bare nanoerythrosomes 43 and a polymeric carrier, 44 and we confirmed this in vitro. Moreover, GA-loaded RBC NPs lifted restrictions on the application of GA, which were due to its poor water solubility.…”

Section: Resultssupporting

confidence: 77%

Gambogic acid-loaded biomimetic nanoparticles in colorectal cancer treatment

Zhang

Yang

et al. 2017

IJN

View full text Add to dashboard Cite

Gambogic acid (GA) is expected to be a potential new antitumor drug, but its poor aqueous solubility and inevitable side effects limit its clinical application. Despite these inhe rent defects, various nanocarriers can be used to promote the solubility and tumor targeting of GA, improving antitumor efficiency. In addition, a cell membrane-coated nanoparticle platform that was reported recently, unites the customizability and flexibility of a synthetic copolymer, as well as the functionality and complexity of natural membrane, and is a new synthetic biomimetic nanocarrier with improved stability and biocompatibility. Here, we combined poly(lactic- co -glycolic acid) (PLGA) with red blood-cell membrane (RBCm), and evaluated whether GA-loaded RBCm nanoparticles can retain and improve the antitumor efficacy of GA with relatively lower toxicity in colorectal cancer treatment compared with free GA. We also confirmed the stability, biocompatibility, passive targeting, and few side effects of RBCm-GA/PLGA nanoparticles. We expect to provide a new drug carrier in the treatment of colorectal cancer, which has strong clinical application prospects. In addition, the potential antitumor drug GA and other similar drugs could achieve broader clinical applications via this biomimetic nanocarrier.

show abstract

Section: Resultssupporting

confidence: 77%

Gambogic acid-loaded biomimetic nanoparticles in colorectal cancer treatment

Zhang

Yang

et al. 2017

IJN

View full text Add to dashboard Cite

show abstract

“…We report here the results of our investigations and explored the effect of dispersion medium on the particle size and zeta potential of the negatively charged lecithin liposomes prepared by thin film hydration method. The thin film method of liposome preparation involves hydration of the thin film (prepared under rotary evaporation) using a suitably dispersion medium for liposome formulation in drug delivery applications [6,[25][26][27][28][29]. This study compares the effect of two dispersion media, i.e., deionized water and buffer (pH 7.4) dispersion medium.…”

Section: Introductionmentioning

confidence: 99%

A Comparative Approach for the Preparation and Physicochemical Characterization of Lecithin Liposomes Using Chloroform and Non‐Halogenated Solvents

Naeem

Kiew

Chung

et al. 2015

J Surfact & Detergents

View full text Add to dashboard Cite

Organic solvents used in various pharmaceutical preparations may be associated with chronic health effects, with special emphasis on halogenated solvents. Liposomes, lipid bilayer membrane carriers, have potential applications in targeted drug delivery systems. The non‐halogenated solvents, acetonitrile and ethanol, were used in comparison to commonly used chloroform. The effect of solvents and dispersion medium was demonstrated using physicochemical properties, stability studies and hemolytic activity. Increased sonication time showed decreased particle size in phosphate buffer saline and water medium. Vesicles prepared from all solvents exhibited better stability in phosphate saline buffer than water when evaluated by particle size and zeta potentials. Liposomes showed a positive zeta potential in buffer solution whereas liposomes in water showed negative zeta potential. In vitro hemolytic activity of liposomes was done with fresh human red blood cells. Results in buffer solution were in the range of 1–4 % which further proved this medium superior to pure water. The findings of this study are helpful in suggesting the formulation of thin films by less hazardous solvents in terms of the environmental integrity and human health.

show abstract

“…As a result, hemolytic anemia will be a consequence as RBCs will not be able to keep the biconcave flexible shape which allows it to squeeze through narrow capillaries with an end result of hemolysis (destruction of RBCs). [14] Pentose phosphate pathway RBCs contain an active pentose phosphate pathway (PPP) for glucose that supplies NADPH (PPP is the only source for NADPH in RBCs). NADPH is important in keeping glutathione in the reduced glutathione.…”

Section: Glucose Transport (Glut-1) Through Rbc Membranementioning

confidence: 99%

Untitled

Payghan

2016

AJP

View full text Add to dashboard Cite

The emerging advances in the development of novel drug delivery technologies are likely to have a significant impact on the drug industry. Among the various carriers used for targeting of drugs to various body tissues, the cellular carriers meet several criteria desirable in clinical applications, among the most important being biocompatibility of carrier and its degradation products. Leukocytes, platelets, erythrocyte, and nanoerythrocytes have been proposed as cellular carrier systems. Among these, the erythrocytes have been the most investigated and have found to possess great potential in novel drug delivery. Most of the nano erythrocytes used as drug carriers are rapidly taken up from blood by macrophages of the reticuloendothelial system (RES), which is present in liver, lung, and spleen of the body. Once in the RES, the erythrocyte is attacked by lysosomal enzymes that cause the breakage of the cellular membrane and the degradation of the hemoglobin by the heme-oxygenase enzyme. The use of red cells as carriers of drugs constitutes a field of work that has been barely explored, especially when compared to other carrier systems. From a therapeutic perspective, erythrocytes may be employed for two main purposes. To act as a reservoir for the drug, providing the sustained release of the same into the body, this enables the posology of the drugs to be modified by altering the dose and increasing the dosage intervals. To selectively direct the drugs to the RES (monocyte-macrophage system) of the liver, spleen, and bone marrow, which constitute the usual sites form the destruction of nanoerythrocytes. Nanoerythrosomes (NERs) are prepared by different erythrocyte ghosts to produce small vesicles with an average diameter of 100 nm. Since the NERs are particles, phagocytosis may be involved in their mechanisms of potentiating drugs such as antineoplastic and angiotensin converting enzyme inhibitors and systemic corticosteroids and prodrug. Such cells could be used as circulating carriers to disseminate a drug within a prolonged period in circulation or in target-specific organs, including the liver, spleen, and lymph nodes. A majority of the drug delivery studies using drug-loaded erythrocytes are in the preclinical phase.

show abstract

Erythrocytes-based synthetic delivery systems: transition from conventional to novel engineering strategies

Cited by 33 publications

References 138 publications

Gambogic acid-loaded biomimetic nanoparticles in colorectal cancer treatment

Gambogic acid-loaded biomimetic nanoparticles in colorectal cancer treatment

A Comparative Approach for the Preparation and Physicochemical Characterization of Lecithin Liposomes Using Chloroform and Non‐Halogenated Solvents

Untitled

Contact Info

Product

Resources

About